Metallo-β-lactamases: Structural features, antibiotic recognition, inhibition, and inhibitor design

Current Topics in Medicinal Chemistry

Volumn 13, Issue 10, 2013, Pages 1242-1253

  Wang, Jing Fang ^a,b,d   Chou, Kuo Chen ^c,d  

^a Shanghai Jiao Tong University   (China)

^b SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d GORDON LIFE SCIENCE INSTITUTE   (United States)

Author keywords

Lactamase; Antibiotics; New Delhi metallo lactamase; Resistance

Indexed keywords

AMPICILLIN; ARYLSULFATASE; ASPARAGINE; ASPARTIC ACID; AZLOCILLIN; BETA LACTAM; CARBENICILLIN; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CYSTEINE; DNA; HISTIDINE; HYDROXYACYLGLUTATHIONE HYDROLASE; IMIPENEM; IRON; LATAMOXEF; MANGANESE; MEROPENEM; METALLO BETA LACTAMASE; NITROCEFIN; PHENYLALANINE DERIVATIVE; PIPERACILLIN; TAZOBACTAM; TICARCILLIN; UNINDEXED DRUG; ZINC;

ANTIBIOTIC RESISTANCE; DRUG DESIGN; DRUG TARGETING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN CLEAVAGE; REVIEW; STENOTROPHOMONAS MALTOPHILIA; STRUCTURAL BIOINFORMATICS;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84878807730     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113139990011     Document Type: Review

References (176)

1. von Nussbaum, F.; Brands, M.; Hinzen, B.; Weigand, S.; Habich, D. Antibacterial natural products in medicinal chemistry--exodus or revival? Angew Chem Int Ed Engl, 2006, 45, 5072-5129.
2. Bounaga, S.; Laws, A. P.; Galleni, M.; Page, M. I. The mechanism of catalysis and the inhibition of the Bacillus cereus zinc-dependent beta-lactamase. Biochem J, 1998, 331 (Pt 3), 703-711.
3. Drawz, S. M.; Bonomo, R. A. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev, 2010, 23, 160-201.
4. Felici, A.; Amicosante, G.; Oratore, A.; Strom, R.; Ledent, P.; Joris, B.; Fanuel, L.; Frere, J. M. An overview of the kinetic parameters of class B beta-lactamases. Biochem J, 1993, 291 (Pt 1), 151-155.
5. Fisher, J. F.; Meroueh, S. O.; Mobashery, S. Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev, 2005, 105, 395-424.
6. Bush, K. Metallo-beta-lactamases: a class apart. Clin Infect Dis, 1998, 27 Suppl 1, S48-53.
7. Page, M. I. The reactivity of beta-lactams, the mechanism of catalysis and the inhibition of beta-lactamases. Curr Pharm Des, 1999, 5, 895-913.
8. Hussain, M.; Carlino, A.; Madonna, M. J.; Lampen, J. O. Cloning and sequencing of the metallothioprotein beta-lactamase II gene of Bacillus cereus 569/H in Escherichia coli. J Bacteriol, 1985, 164, 223-229.
9. Sabath, L. D.; Abraham, E. P. Zinc as a cofactor for cephalosporinase from Bacillus cereus 569. Biochem J, 1966, 98, 11C-13C.
10. Laraki, N.; Franceschini, N.; Rossolini, G. M.; Santucci, P.; Meunier, C.; de Pauw, E.; Amicosante, G.; Frere, J. M.; Galleni, M. Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-beta-lactamase IMP-1 produced by Escherichia coli. Antimicrob Agents Chemother, 1999, 43, 902-906.
11. Massidda, O.; Rossolini, G. M.; Satta, G. The Aeromonas hydrophila cphA gene: molecular heterogeneity among class B metallo-beta-lactamases. J Bacteriol, 1991, 173, 4611-4617.
12. Sanschagrin, F.; Dufresne, J.; Levesque, R. C. Molecular heterogeneity of the L-1 metallo-beta-lactamase family from Stenotrophomonas maltophilia. Antimicrob Agents Chemother, 1998, 42, 1245-1248.
13. Dea-Ayuela, M. A.; Perez-Castillo, Y.; Meneses-Marcel, A.; Ubeira, F. M.; Bolas-Fernandez, F.; Chou, K. C.; Gonzalez-Diaz, H. HP-Lattice QSAR for dynein proteins: Experimental proteomics (2D-electrophoresis, mass spectrometry) and theoretic study of a Leishmania infantum sequence. Bioorg Med Chem, 2008, 16, 7770-7776.
14. Du, Q. S.; Huang, R. B.; Wei, Y. T.; Du, L. Q.; Chou, K. C. Multiple Field Three Dimensional Quantitative Structure-Activity Relationship (MF-3D-QSAR). J. Comput. Chem., 2008, 29, 211-219.
15. Prado-Prado, F. J.; Gonzalez-Diaz, H.; de la Vega, O. M.; Ubeira, F. M.; Chou, K. C. Unified QSAR approach to antimicrobials. Part 3: First multi-tasking QSAR model for Input-Coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorganic & Medicinal Chemistry, 2008, 16, 5871-5880.
16. Prado-Prado, F. J.; Martinez de la Vega O.; Uriarte, E.; Ubeira, F. M.; Chou, K. C.; Gonzalez-Diaz, H. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorg Med Chem, 2009, 17, 569-575.
17. Wei, H.; Wang, C. H.; Du, Q. S.; Meng, J.; Chou, K. C. Investigation into adamantane-based M2 inhibitors with FB-QSAR. Medicinal Chemistry, 2009, 5, 305-317.
18. Du, Q. S.; Huang, R. B.; Wei, Y. T.; Pang, Z. W.; Du, L. Q.; Chou, K. C. Fragment-Based Quantitative Structure-Activity Relationship (FB-QSAR) for Fragment-Based Drug Design. J. Comput. Chem., 2009, 30, 295-304.
19. Liu, L.; Ma, Y.; Wang, R. L.; Xu, W. R.; Wang, S. Q.; Chou, K. C. Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics. Drug Design, Development and Therapy, 2013, open access to scientific and medical research.
20. Chou, K. C. Insights from modelling three-dimensional structures of the human potassium and sodium channels. Journal of Proteome Research, 2004, 3, 856-861.
21. Chou, K. C. Insights from modelling the tertiary structure of BACE2. Journal of Proteome Research, 2004, 3, 1069-1072.
22. Ma, Y.; Wang, S. Q.; Xu, W. R.; Wang, R. L.; Chou, K. C. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One, 2012, 7, e38546.
23. Chou, K. C. Insights from modeling the 3D structure of DNA-CBF3b complex. Journal of Proteome Research, 2005, 4, 1657-1660.
24. Du, Q. S.; Wang, S. Q.; Chou, K. C. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Biochem Biophys Res Comm, 2007, 362, 525-531.
25. Chou, K. C.; Jones, D.; Heinrikson, R. L. Prediction of the tertiary structure and substrate binding site of caspase-8. FEBS Lett., 1997, 419, 49-54.
26. Du, Q. S.; Huang, R. B.; Wang, S. Q.; Chou, K. C. Designing inhibitors of M2 proton channel against H1N1 swine influenza virus. PLoS ONE, 2010, 5, e9388.
27. Chou, K. C.; Tomasselli, A. G.; Heinrikson, R. L. Prediction of the Tertiary Structure of a Caspase-9/Inhibitor Complex. FEBS Lett., 2000, 470, 249-256.
28. Chou, K. C. The convergence-divergence duality in lectin domains of the selectin family and its implications. FEBS Lett., 1995, 363, 123-126.
29. Wang, S. Q.; Du, Q. S.; Chou, K. C. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem Biophys Res Comm, 2007, 354, 634-640.
30. Chou, K. C. Coupling interaction between thromboxane A2 receptor and alpha-13 subunit of guanine nucleotide-binding protein. Journal of Proteome Research, 2005, 4, 1681-1686.
31. Li, X. B.; Wang, S. Q.; Xu, W. R.; Wang, R. L.; Chou, K. C. Novel Inhibitor Design for Hemagglutinin against H1N1 Influenza Virus by Core Hopping Method. PLoS One, 2011, 6, e28111.
32. Chou, K. C.; Howe, W. J. Prediction of the tertiary structure of the beta-secretase zymogen. Biochem. Biophys. Res. Commun., 2002, 292, 702-708.
33. Jiang, Y.; Huang, T.; Lei, C.; Gao, Y. F.; Cai, Y. D.; Chou, K. C. Signal propagation in protein interaction network during colorectal cancer progression. BioMed Research International, openly accssible at http://www.hindawi.com/journals/bmri/2013/287019/, 2013, 2013, 1-9.
34. Chen, W.; Lin, H.; Feng, P. M.; Ding, C.; Zuo, Y. C.; Chou, K. C. iNuc-PhysChem: A Sequence-Based Predictor for Identifying Nucleosomes via Physicochemical Properties. PLoS ONE, 2012, 7, e47843.
35. Chen, W.; Feng, P. M.; Lin, H.; Chou, K. C. iRSpot-PseDNC: identify recombination spots with pseudo dinucleotide composition. Nucleic Acids Res., 2013, 41, e68.
36. Xiao, X.; Wang, P.; Lin, W. Z.; Jia, J. H.; Chou, K. C. iAMP-2L: A two-level multi-label classifier for identifying antimicrobial peptides and their functional types. Anal. Biochem., 2013, 436, 168-177.
37. Lin, W. Z.; Fang, J. A.; Xiao, X.; Chou, K. C. Predicting Secretory Proteins of Malaria Parasite by Incorporating Sequence Evolution Information into Pseudo Amino Acid Composition via Grey System Model. PLoS One, 2012, 7, e49040.
38. Chou, K. C. A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins. J. Biol. Chem., 1993, 268, 16938-16948.
39. Chou, K. C. Review: Prediction of human immunodeficiency virus protease cleavage sites in proteins. Anal. Biochem., 1996, 233, 1-14.
40. Li, B. Q.; Huang, T.; Liu, L.; Cai, Y. D.; Chou, K. C. Identification of colorectal cancer related genes with mRMR and shortest path in protein-protein interaction network. PLoS ONE, 2012, 7, e33393.
41. Chou, K. C.; Shen, H. B. Signal-CF: a subsite-coupled and window-fusing approach for predicting signal peptides. Biochem Biophys Res Comm, 2007, 357, 633-640.
42. Chou, K. C.; Wu, Z. C.; Xiao, X. iLoc-Hum: Using accumulation-label scale to predict subcellular locations of human proteins with both single and multiple sites. Molecular Biosystems, 2012, 8, 629-641.
43. Lin, W. Z.; Fang, J. A.; Xiao, X.; Chou, K. C. iLoc-Animal: A multi-label learning classifier for predicting subcellular localization of animal proteins Molecular BioSystems, 2013, 9, 634-644.
44. Chou, K. C. Some Remarks on Predicting Multi-Label Attributes in Molecular Biosystems. Molecular Biosystems, 2013, 9, 1092-1100.
45. Lin, W. Z.; Fang, J. A.; Xiao, X.; Chou, K. C. iDNA-Prot: Identification of DNA Binding Proteins Using Random Forest with Grey Model. PLoS ONE, 2011, 6, e24756.
46. Chou, K. C.; Shen, H. B. ProtIdent: A web server for identifying proteases and their types by fusing functional domain and sequential evolution information. Biochem. Biophys. Res. Comm., 2008, 376, 321-325.
47. Wang, P.; Xiao, X.; Chou, K. C. NR-2L: A Two-Level Predictor for Identifying Nuclear Receptor Subfamilies Based on Sequence-Derived Features. PLoS ONE, 2011, 6, e23505.
48. Xiao, X.; Wang, P.; Chou, K. C. GPCR-2L: Predicting G protein-coupled receptors and their types by hybridizing two different modes of pseudo amino acid compositions. Molecular Biosystems, 2011, 7, 911-919.
49. Huang, T.; Wang, J.; Cai, Y. D.; Yu, H.; Chou, K. C. Hepatitis C virus network based classification of hepatocellular cirrhosis and carcinoma. PLoS ONE, 2012, 7, e34460.
50. Chen, L.; Zeng, W. M.; Cai, Y. D.; Feng, K. Y.; Chou, K. C. Predicting Anatomical Therapeutic Chemical (ATC) classification of drugs by integrating chemical-chemical interactions and similarities. PLoS ONE, 2012, 7, e35254.
51. Huang, T.; Zhang, J.; Xu, Z. P.; Hu, L. L.; Chen, L.; Shao, J. L.; Zhang, L.; Kong, X. Y.; Cai, Y. D.; Chou, K. C. Deciphering the effects of gene deletion on yeast longevity using network and machine learning approaches. Biochimie, 2012, 94, 1017-1025.
52. Xu, Y.; Ding, J.; Wu, L. Y.; Chou, K. C. iSNO-PseAAC: Predict cysteine S-nitrosylation sites in proteins by incorporating position specific amino acid propensity into pseudo amino acid composition PLoS ONE, 2013, 8, e55844.
53. Chou, K. C.; Shen, H. B. Review: recent advances in developing web-servers for predicting protein attributes (doi: 10.4236/ns.2009.12011). Natural Science, 2009, 2, 63-92 (openly accessible at http://www.scirp.org/journal/NS/)
54. Chou, K. C. Some remarks on protein attribute prediction and pseudo amino acid composition (50th Anniversary Year Review). J. Theor. Biol., 2011, 273, 236-247.
55. Chou, K. C. Review: Structural bioinformatics and its impact to biomedical science. Current Medicinal Chemistry, 2004, 11, 2105-2134.
56. Chou, K. C.; Wei, D. Q.; Zhong, W. Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. (Erratum: ibid., 2003, Vol.310, 675). Biochem Biophys Res Comm, 2003, 308, 148-151.
57. Yong, D.; Toleman, M. A.; Giske, C. G.; Cho, H. S.; Sundman, K.; Lee, K.; Walsh, T. R. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother, 2009, 53, 5046-5054.
58. Ambler, R. P. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci, 1980, 289, 321-331.
59. Garau, G.; Garcia-Saez, I.; Bebrone, C.; Anne, C.; Mercuri, P.; Galleni, M.; Frere, J. M.; Dideberg, O. Update of the standard numbering scheme for class B beta-lactamases. Antimicrob Agents Chemother, 2004, 48, 2347-2349.
60. Osano, E.; Arakawa, Y.; Wacharotayankun, R.; Ohta, M.; Horii, T.; Ito, H.; Yoshimura, F.; Kato, N. Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother, 1994, 38, 71-78.
61. Poirel, L.; Naas, T.; Nicolas, D.; Collet, L.; Bellais, S.; Cavallo, J. D.; Nordmann, P. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid-and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother, 2000, 44, 891-897.
62. Borra, P. S.; Leiros, H. K.; Ahmad, R.; Spencer, J.; Leiros, I.; Walsh, T. R.; Sundsfjord, A.; Samuelsen, O. Structural and computational investigations of VIM-7: insights into the substrate specificity of vim metallo-beta-lactamases. J Mol Biol, 2011, 411, 174-189.
63. Carfi, A.; Duee, E.; Galleni, M.; Frere, J. M.; Dideberg, O. 1.85 A resolution structure of the zinc (II) beta-lactamase from Bacillus cereus. Acta Crystallogr D Biol Crystallogr, 1998, 54, 313-323.
64. Concha, N. O.; Janson, C. A.; Rowling, P.; Pearson, S.; Cheever, C. A.; Clarke, B. P.; Lewis, C.; Galleni, M.; Frere, J. M.; Payne, D. J.; Bateson, J. H.; Abdel-Meguid, S. S. Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor. Biochemistry, 2000, 39, 4288-4298.
65. Concha, N. O.; Rasmussen, B. A.; Bush, K.; Herzberg, O. Crystal structure of the wide-spectrum binuclear zinc beta-lactamase from Bacteroides fragilis. Structure, 1996, 4, 823-836.
66. Docquier, J. D.; Benvenuti, M.; Calderone, V.; Stoczko, M.; Menciassi, N.; Rossolini, G. M.; Mangani, S. High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. Antimicrob Agents Chemother, 2010, 54, 4343-4351.
67. Fabiane, S. M.; Sohi, M. K.; Wan, T.; Payne, D. J.; Bateson, J. H.; Mitchell, T.; Sutton, B. J. Crystal structure of the zinc-dependent beta-lactamase from Bacillus cereus at 1.9 A resolution: binuclear active site with features of a mononuclear enzyme. Biochemistry, 1998, 37, 12404-12411.
68. Garau, G.; Bebrone, C.; Anne, C.; Galleni, M.; Frere, J. M.; Dideberg, O. A metallo-beta-lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with biapenem. J Mol Biol, 2005, 345, 785-795.
69. Garcia-Saez, I.; Docquier, J. D.; Rossolini, G. M.; Dideberg, O. The three-dimensional structure of VIM-2, a Zn-beta-lactamase from Pseudomonas aeruginosa in its reduced and oxidised form. J Mol Biol, 2008, 375, 604-611.
70. Garcia-Saez, I.; Hopkins, J.; Papamicael, C.; Franceschini, N.; Amicosante, G.; Rossolini, G. M.; Galleni, M.; Frere, J. M.; Dideberg, O. The 1.5-A structure of Chryseobacterium meningosepticum zinc beta-lactamase in complex with the inhibitor, D-captopril. J Biol Chem, 2003, 278, 23868-23873.
71. Garcia-Saez, I.; Mercuri, P. S.; Papamicael, C.; Kahn, R.; Frere, J. M.; Galleni, M.; Rossolini, G. M.; Dideberg, O. Three-dimensional structure of FEZ-1, a monomeric subclass B3 metallo-beta-lactamase from Fluoribacter gormanii, in native form and in complex with D-captopril. J Mol Biol, 2003, 325, 651-660.
72. Murphy, T. A.; Catto, L. E.; Halford, S. E.; Hadfield, A. T.; Minor, W.; Walsh, T. R.; Spencer, J. Crystal structure of Pseudomonas aeruginosa SPM-1 provides insights into variable zinc affinity of metallo-beta-lactamases. J Mol Biol, 2006, 357, 890-903.
73. Ullah, J. H.; Walsh, T. R.; Taylor, I. A.; Emery, D. C.; Verma, C. S.; Gamblin, S. J.; Spencer, J. The crystal structure of the L1 metallo-beta-lactamase from Stenotrophomonas maltophilia at 1.7 A resolution. J Mol Biol, 1998, 284, 125-136.
74. Daiyasu, H.; Osaka, K.; Ishino, Y.; Toh, H. Expansion of the zinc metallo-hydrolase family of the beta-lactamase fold. FEBS Lett, 2001, 503, 1-6.
75. Campos-Bermudez, V. A.; Gonzalez, J. M.; Tierney, D. L.; Vila, A. J. Spectroscopic signature of a ubiquitous metal binding site in the metallo-beta-lactamase superfamily. J Biol Inorg Chem, 2010, 15, 1209-1218.
76. Davies, R. B.; Abraham, E. P. Metal cofactor requirements of beta-lactamase II. Biochem J, 1974, 143, 129-135.
77. Hernandez Valladares, M.; Felici, A.; Weber, G.; Adolph, H. W.; Zeppezauer, M.; Rossolini, G. M.; Amicosante, G.; Frere, J. M.; Galleni, M. Zn(II) dependence of the Aeromonas hydrophila AE036 metallo-beta-lactamase activity and stability. Biochemistry, 1997, 36, 11534-11541.
78. Bebrone, C. Metallo-beta-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. Biochem Pharmacol, 2007, 74, 1686-1701.
79. Avison, M. B.; Higgins, C. S.; von Heldreich, C. J.; Bennett, P. M.; Walsh, T. R. Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother, 2001, 45, 413-419.
80. Bellais, S.; Leotard, S.; Poirel, L.; Naas, T.; Nordmann, P. Molecular characterization of a carbapenem-hydrolyzing beta-lactamase from Chryseobacterium (Flavobacterium) indologenes. FEMS Microbiol Lett, 1999, 171, 127-132.
81. Bellais, S.; Naas, T.; Nordmann, P. Genetic and biochemical characterization of CGB-1, an Ambler class B carbapenem-hydrolyzing beta-lactamase from Chryseobacterium gleum. Antimicrob Agents Chemother, 2002, 46, 2791-2796.
82. Bellais, S.; Poirel, L.; Leotard, S.; Naas, T.; Nordmann, P. Genetic diversity of carbapenem-hydrolyzing metallo-beta-lactamases from Chryseobacterium (Flavobacterium) indologenes. Antimicrob Agents Chemother, 2000, 44, 3028-3034.
83. Chen, Y.; Succi, J.; Tenover, F. C.; Koehler, T. M. Beta-lactamase genes of the penicillin-susceptible Bacillus anthracis Sterne strain. J Bacteriol, 2003, 185, 823-830.
84. Docquier, J. D.; Pantanella, F.; Giuliani, F.; Thaller, M. C.; Amicosante, G.; Galleni, M.; Frere, J. M.; Bush, K.; Rossolini, G. M. CAU-1, a subclass B3 metallo-beta-lactamase of low substrate affinity encoded by an ortholog present in the Caulobacter crescentus chromosome. Antimicrob Agents Chemother, 2002, 46, 1823-1830.
85. Lim, H. M.; Pene, J. J.; Shaw, R. W. Cloning, nucleotide sequence, and expression of the Bacillus cereus 5/B/6 beta-lactamase II structural gene. J Bacteriol, 1988, 170, 2873-2878.
86. Mammeri, H.; Bellais, S.; Nordmann, P. Chromosome-encoded beta-lactamases TUS-1 and MUS-1 from Myroides odoratus and Myroides odoratimimus (formerly Flavobacterium odoratum), new members of the lineage of molecular subclass B1 metalloenzymes. Antimicrob Agents Chemother, 2002, 46, 3561-3567.
87. Naas, T.; Bellais, S.; Nordmann, P. Molecular and biochemical characterization of a carbapenem-hydrolysing beta-lactamase from Flavobacterium johnsoniae. J Antimicrob Chemother, 2003, 51, 267-273.
88. Rossolini, G. M.; Condemi, M. A.; Pantanella, F.; Docquier, J. D.; Amicosante, G.; Thaller, M. C. Metallo-beta-lactamase producers in environmental microbiota: new molecular class B enzyme in Janthinobacterium lividum. Antimicrob Agents Chemother, 2001, 45, 837-844.
89. Rossolini, G. M.; Franceschini, N.; Riccio, M. L.; Mercuri, P. S.; Perilli, M.; Galleni, M.; Frere, J. M.; Amicosante, G. Characterization and sequence of the Chryseobacterium (Flavobacterium) meningosepticum carbapenemase: a new molecular class B beta-lactamase showing a broad substrate profile. Biochem J, 1998, 332 (Pt 1), 145-152.
90. Saavedra, M. J.; Peixe, L.; Sousa, J. C.; Henriques, I.; Alves, A.; Correia, A. Sfh-I, a subclass B2 metallo-beta-lactamase from a Serratia fonticola environmental isolate. Antimicrob Agents Chemother, 2003, 47, 2330-2333.
91. Simm, A. M.; Higgins, C. S.; Pullan, S. T.; Avison, M. B.; Niumsup, P.; Erdozain, O.; Bennett, P. M.; Walsh, T. R. A novel metallo-beta-lactamase, Mbl1b, produced by the environmental bacterium Caulobacter crescentus. FEBS Lett, 2001, 509, 350-354.
92. Walsh, T. R.; Hall, L.; Assinder, S. J.; Nichols, W. W.; Cartwright, S. J.; MacGowan, A. P.; Bennett, P. M. Sequence analysis of the L1 metallo-beta-lactamase from Xanthomonas maltophilia. Biochim Biophys Acta, 1994, 1218, 199-201.
93. Walsh, T. R.; Neville, W. A.; Haran, M. H.; Tolson, D.; Payne, D. J.; Bateson, J. H.; MacGowan, A. P.; Bennett, P. M. Nucleotide and amino acid sequences of the metallo-beta-lactamase, ImiS, from Aeromonas veronii bv. sobria. Antimicrob Agents Chemother, 1998, 42, 436-439.
94. Woodford, N.; Palepou, M. F.; Babini, G. S.; Holmes, B.; Livermore, D. M. Carbapenemases of Chryseobacterium (Flavobacterium) meningosepticum: distribution of blaB and characterization of a novel metallo-beta-lactamase gene, blaB3, in the type strain, NCTC 10016. Antimicrob Agents Chemother, 2000, 44, 1448-1452.
95. Yang, Y.; Bush, K. Biochemical characterization of the carbapenem-hydrolyzing beta-lactamase AsbM1 from Aeromonas sobria AER 14M: a member of a novel subgroup of metallo-betalactamases. FEMS Microbiol Lett, 1996, 137, 193-200.
96. Spencer, J.; Read, J.; Sessions, R. B.; Howell, S.; Blackburn, G. M.; Gamblin, S. J. Antibiotic recognition by binuclear metallobeta-lactamases revealed by X-ray crystallography. J Am Chem Soc, 2005, 127, 14439-14444.
97. He, Z.; Zhang, J.; Shi, X. H.; Hu, L. L.; Kong, X.; Cai, Y. D.; Chou, K. C. Predicting drug-target interaction networks based on functional groups and biological features. PLoS ONE, 2010, 5, e9603.
98. Schnell, J. R.; Chou, J. J. Structure and mechanism of the M2 proton channel of influenza A virus. Nature, 2008, 451, 591-595.
99. Pielak, R. M.; Jason R.; Schnell, J. R.; Chou, J. J. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proceedings of National Academy of Science, USA, 2009, 106, 7379-7384.
100. Du, Q. S.; Wang, S.; Wei, D. Q.; Sirois, S.; Chou, K. C. Molecular modelling and chemical modification for finding peptide inhibitor against SARS CoV Mpro. Anal. Biochem., 2005, 337, 262-270.
101. Huang, R. B.; Du, Q. S.; Wang, C. H.; Chou, K. C. An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus. Biochem. Biophys. Res. Comm., 2008, 377, 1243-1247.
102. Du, Q. S.; Huang, R. B.; Wang, C. H.; Li, X. M.; Chou, K. C. Energetic analysis of the two controversial drug binding sites of the M2 proton channel in influenza A virus. J. Theor. Biol., 2009, 259, 159-164.
103. Wang, S. Q.; Du, Q. S.; Huang, R. B.; Zhang, D. W.; Chou, K. C. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. Biochem. Biophys. Res. Commun., 2009, 386, 432-436.
104. Cai, L.; Wang, Y.; Wang, J. F.; Chou, K. C. Identification of Proteins Interacting with Human SP110 During the Process of Viral Infections. Medicinal Chemistry, 2011, 7, 121-126.
105. Liao, Q. H.; Gao, Q. Z.; Wei, J.; Chou, K. C. Docking and Molecular Dynamics Study on the Inhibitory Activity of Novel Inhibitors on Epidermal Growth Factor Receptor (EGFR). Medicinal Chemistry, 2011, 7, 24-31.
106. Wang, J. F.; Chou, K. C. Insights from modeling the 3D structure of New Delhi metallo-beta-lactamase and its binding interactions with antibiotic drugs. PLoS ONE 2011, 6, e18414.
107. Wang, J. F.; Chou, K. C. Insights into the mutation-induced HHH syndrome from modeling human mitochondrial ornithine transporter-1. PLoS One, 2012, 7, e31048.
108. Chou, K. C.; Chen, N. Y. The biological functions of lowfrequency phonons. Scientia Sinica, 1977, 20, 447-457.
109. Chou, K. C. Identification of low-frequency modes in protein molecules. Biochem. J., 1983, 215, 465-469.
110. Martel, P. Biophysical aspects of neutron scattering from vibrational modes of proteins. Prog Biophys Mol Biol, 1992, 57, 129-179.
111. Chou, K. C. Low-frequency vibration of DNA molecules. Biochem. J., 1984, 221, 27-31.
112. Chou, K. C. Low-frequency motions in protein molecules: betasheet and beta-barrel. Biophys. J., 1985, 48, 289-297.
113. Chou, K. C.; Maggiora, G. M.; Mao, B. Quasi-continuum models of twist-like and accordion-like low-frequency motions in DNA. Biophys. J., 1989, 56, 295-305.
114. Chou, K. C. Biological functions of low-frequency vibrations (phonons). III. Helical structures and microenvironment. Biophys. J., 1984, 45, 881-889.
115. Wang, J. F.; Chou, K. C. Insight into the molecular switch mechanism of human Rab5a from molecular dynamics simulations. Biochem. Biophys. Res. Commun., 2009, 390, 608-612.
116. Chou, K. C. Low-frequency resonance and cooperativity of hemoglobin. Trends Biochem. Sci., 1989, 14, 212-213.
117. Chou, K. C. The biological functions of low-frequency phonons. 4. Resonance effects and allosteric transition. Biophysical Chemistry, 1984, 20, 61-71.
118. Chou, K. C. The biological functions of low-frequency phonons: 6. A possible dynamic mechanism of allosteric transition in antibody molecules. Biopolymers, 1987, 26, 285-295.
119. Chou, K. C.; Mao, B. Collective motion in DNA and its role in drug intercalation. Biopolymers, 1988, 27, 1795-1815.
120. Chou, K. C.; Zhang, C. T.; Maggiora, G. M. Solitary wave dynamics as a mechanism for explaining the internal motion during microtubule growth. Biopolymers, 1994, 34, 143-153.
121. Chou, K. C. Review: Low-frequency collective motion in biomacromolecules and its biological functions. Biophysical Chemistry, 1988, 30, 3-48.
122. Gordon, G. Extrinsic electromagnetic fields, low frequency (phonon) vibrations, and control of cell function: a non-linear resonance system. Journal of Biomedical Science and Engineering (JBiSE), 2008, 1, 152-156 (open accessible at http://www.srpublishing.org/journal/jbise/).
123. Gordon, G. Designed Electromagnetic Pulsed Therapy: Clinical Applications. J. Cell. Physiol., 2007, 212, 579-582.
124. Madkan, A.; Blank, M.; Elson, E.; Chou, K. C.; Geddis, M. S.; Goodman, R. Steps to the clinic with ELF EMF (doi:10.4236/ns.2009.13020). Natural Science 2009, 1, 157-165 (openly accessible at http://www.scirp.org/journal/NS/).
125. Zeng, Q. K.; Du, H. L.; Wang, J. F.; Wei, D. Q.; Wang, X. N.; Li, Y. X.; Lin, Y. Reversal of coenzyme specificity and improvement of catalytic efficiency of Pichia stipitis xylose reductase by rational site-directed mutagenesis. Biotechnol Lett, 2009, 31, 1025-1029.
126. Wang, J. F.; Wei, D. Q.; Li, L.; Zheng, S. Y.; Li, Y. X.; Chou, K. C. 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. Biochem Biophys Res Commun, 2007, 355, 513-519.
127. Wang, J. F.; Wei, D. Q.; Chen, C.; Li, Y.; Chou, K. C. Molecular modeling of two CYP2C19 SNPs and its implications for personalized drug design. Protein Pept Lett, 2008, 15, 27-32.
128. Wang, J. F.; Chou, K. C. Insights from modeling the 3D structure of New Delhi metallo-beta-lactamse and its binding interactions with antibiotic drugs. PLoS One, 2011, 6, e18414.
129. Wang, J. F.; Chou, K. C. Molecular modeling of cytochrome P450 and drug metabolism. Curr Drug Metab, 2010, 11, 342-346.
130. Wang, J. F.; Chou, K. C. Insight into the molecular switch mechanism of human Rab5a from molecular dynamics simulations. Biochem Biophys Res Commun, 2009, 390, 608-612.
131. Li, J.; Wei, D. Q.; Wang, J. F.; Yu, Z. T.; Chou, K. C. Molecular dynamics simulations of CYP2E1. Med Chem, 2012, 8, 208-221.
132. He, J.; Wei, D. Q.; Wang, J. F.; Chou, K. C. Predicting proteinligand binding sites based on an improved geometric algorithm. Protein Pept Lett, 2011, 18, 997-1001.
133. Chen, Q.; Zhang, T.; Wang, J. F.; Wei, D. Q. Advances in human cytochrome p450 and personalized medicine. Curr Drug Metab, 2011, 12, 436-444.
134. Wang, J. F.; Chou, K. C. Insights from studying the mutationinduced allostery in the M2 proton channel by molecular dynamics. Protein Eng Des Sel, 2010, 23, 663-666.
135. Tang, B.; Gong, K.; Wang, J. F.; Li, Y. X.; Wei, D. Q. The structure of phospholamban and its MD simulations. Chinese Sci Bull, 2010, 55, 1619-1624.
136. Zhang, L. S.; Wang, S. Q.; Xu, W. R.; Wang, R. L.; Wang, J. F. Scaffold-Based Pan-Agonist Design for the PPARalpha, PPARbeta and PPARgamma Receptors. PLoS One, 2012, 7, e48453.
137. Wang, J. F.; Chou, K. C. Recent advances in computational studies on influenza a virus M2 proton channel. Mini Rev Med Chem, 2012, 12, 971-978.
138. Wang, J. F.; Yan, J. Y.; Wei, D. Q.; Chou, K. C. Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism. Med Chem, 2009, 5, 263-270.
139. Ping, J.; Wang, Y. J.; Wang, J. F.; Li, X.; Li, Y. X.; Hao, P. Negatively cooperative binding properties of human cytochrome P450 2E1 with monocyclic substrates. Curr Drug Metab, 2012, 13, 1024-1031.
140. Lian, P.; Wei, D. Q.; Wang, J. F.; Chou, K. C. An allosteric mechanism inferred from molecular dynamics simulations on phospholamban pentamer in lipid membranes. PLoS One, 2011, 6, e18587.
141. Li, J.; Wei, D. Q.; Wang, J. F.; Li, Y. X. A negative cooperativity mechanism of human CYP2E1 inferred from molecular dynamics simulations and free energy calculations. J Chem Inf Model, 2011, 51, 3217-3225.
142. Gu, H.; Chen, H. F.; Wei, D. Q.; Wang, J. F. Molecular dynamics simulations exploring drug resistance in HIV-1 protease. Chinese Sci Bull, 2010, 55, 2677-2683.
143. Wang, J. F.; Wei, D. Q.; Chou, K. C. Drug candidates from traditional chinese medicines. Curr Top Med Chem, 2008, 8, 16561665.
144. Guo, X.; Wang, J. F.; Zhu, Y.; Wei, D. Q. Recent Progress on Computer-Aided Inhibitor Design of H5N1 Influenza A Virus. Curr Comput Aided Drug Des, 2010, 6, 139-146.
145. Wang, Z.; Fast, W.; Benkovic, S. J. On the mechanism of the metallo-beta-lactamase from Bacteroides fragilis. Biochemistry, 1999, 38, 10013-10023.
146. Park, H.; Brothers, E. N.; Merz, K. M., Jr. Hybrid QM/MM and DFT investigations of the catalytic mechanism and inhibition of the dinuclear zinc metallo-beta-lactamase CcrA from Bacteroides fragilis. J Am Chem Soc, 2005, 127, 4232-4241.
147. Crowder, M. W.; Spencer, J.; Vila, A. J. Metallo-beta-lactamases: novel weaponry for antibiotic resistance in bacteria. Acc Chem Res, 2006, 39, 721-728.
148. Wu, S.; Xu, D.; Guo, H. QM/MM studies of monozinc betalactamase CphA suggest that the crystal structure of an enzymeintermediate complex represents a minor pathway. J Am Chem Soc, 2010, 132, 17986-17988.
149. Bebrone, C.; Delbruck, H.; Kupper, M. B.; Schlomer, P.; Willmann, C.; Frere, J. M.; Fischer, R.; Galleni, M.; Hoffmann, K. M. The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site. Antimicrob Agents Chemother, 2009, 53, 4464-4471.
150. Simona, F.; Magistrato, A.; Dal Peraro, M.; Cavalli, A.; Vila, A. J.; Carloni, P. Common mechanistic features among metallo-betalactamases: a computational study of Aeromonas hydrophila CphA enzyme. J Biol Chem, 2009, 284, 28164-28171.
151. Miller, L. A.; Ratnam, K.; Payne, D. J. Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr Opin Pharmacol, 2001, 1, 451-458.
152. Toney, J. H. Metallo-beta-lactamase inhibitors: could they give old antibacterials new life? Curr Opin Investig Drugs, 2003, 4, 115-116.
153. Toney, J. H.; Cleary, K. A.; Hammond, G. G.; Yuan, X.; May, W. J.; Hutchins, S. M.; Ashton, W. T.; Vanderwall, D. E. Structureactivity relationships of biphenyl tetrazoles as metallo-betalactamase inhibitors. Bioorg Med Chem Lett, 1999, 9, 2741-2746.
154. Toney, J. H.; Fitzgerald, P. M.; Grover-Sharma, N.; Olson, S. H.; May, W. J.; Sundelof, J. G.; Vanderwall, D. E.; Cleary, K. A.; Grant, S. K.; Wu, J. K.; Kozarich, J. W.; Pompliano, D. L.; Hammond, G. G. Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-beta-lactamase. Chem Biol, 1998, 5, 185-196.
155. Bounaga, S.; Galleni, M.; Laws, A. P.; Page, M. I. Cysteinyl peptide inhibitors of Bacillus cereus zinc beta-lactamase. Bioorg Med Chem, 2001, 9, 503-510.
156. Buynak, J. D.; Chen, H.; Vogeti, L.; Gadhachanda, V. R.; Buchanan, C. A.; Palzkill, T.; Shaw, R. W.; Spencer, J.; Walsh, T. R. Penicillin-derived inhibitors that simultaneously target both metalloand serine-beta-lactamases. Bioorg Med Chem Lett, 2004, 14, 1299-1304.
157. Payne, D. J.; Du, W.; Bateson, J. H. beta-Lactamase epidemiology and the utility of established and novel beta-lactamase inhibitors. Expert Opin Investig Drugs, 2000, 9, 247-261.
158. Payne, D. J.; Bateson, J. H.; Gasson, B. C.; Khushi, T.; Proctor, D.; Pearson, S. C.; Reid, R. Inhibition of metallo-beta-lactamases by a series of thiol ester derivatives of mercaptophenylacetic acid. FEMS Microbiol Lett, 1997, 157, 171-175.
159. Hammond, G. G.; Huber, J. L.; Greenlee, M. L.; Laub, J. B.; Young, K.; Silver, L. L.; Balkovec, J. M.; Pryor, K. D.; Wu, J. K.; Leiting, B.; Pompliano, D. L.; Toney, J. H. Inhibition of IMP-1 metallo-beta-lactamase and sensitization of IMP-1-producing bacteria by thioester derivatives. FEMS Microbiol Lett, 1999, 179, 289-296.
160. Fitzgerald, P. M.; Wu, J. K.; Toney, J. H. Unanticipated inhibition of the metallo-beta-lactamase from Bacteroides fragilis by 4morpholineethanesulfonic acid (MES): a crystallographic study at 1.85-A resolution. Biochemistry, 1998, 37, 6791-6800.
161. Siemann, S.; Clarke, A. J.; Viswanatha, T.; Dmitrienko, G. I. Thiols as classical and slow-binding inhibitors of IMP-1 and other binuclear metallo-beta-lactamases. Biochemistry, 2003, 42, 1673-1683.
162. Scrofani, S. D.; Chung, J.; Huntley, J. J.; Benkovic, S. J.; Wright, P. E.; Dyson, H. J. NMR characterization of the metallo-beta-lactamase from Bacteroides fragilis and its interaction with a tight-binding inhibitor: role of an active-site loop. Biochemistry, 1999, 38, 14507-14514.
163. Mollard, C.; Moali, C.; Papamicael, C.; Damblon, C.; Vessilier, S.; Amicosante, G.; Schofield, C. J.; Galleni, M.; Frere, J. M.; Roberts, G. C. Thiomandelic acid, a broad spectrum inhibitor of zinc beta-lactamases: kinetic and spectroscopic studies. J Biol Chem, 2001, 276, 45015-45023.
164. Kurosaki, H.; Yasuzawa, H.; Yamaguchi, Y.; Jin, W.; Arakawa, Y.; Goto, M. Detection of a metallo-beta-lactamase (IMP-1) by fluorescent probes having dansyl and thiol groups. Org Biomol Chem, 2003, 1, 17-20.
165. Jin, W.; Arakawa, Y.; Yasuzawa, H.; Taki, T.; Hashiguchi, R.; Mitsutani, K.; Shoga, A.; Yamaguchi, Y.; Kurosaki, H.; Shibata, N.; Ohta, M.; Goto, M. Comparative study of the inhibition of metallo-beta-lactamases (IMP-1 and VIM-2) by thiol compounds that contain a hydrophobic group. Biol Pharm Bull, 2004, 27, 851-856.
166. Goto, M.; Takahashi, T.; Yamashita, F.; Koreeda, A.; Mori, H.; Ohta, M.; Arakawa, Y. Inhibition of the metallo-beta-lactamase produced from Serratia marcescens by thiol compounds. Biol Pharm Bull, 1997, 20, 1136-1140.
167. Arakawa, Y.; Shibata, N.; Shibayama, K.; Kurokawa, H.; Yagi, T.; Fujiwara, H.; Goto, M. Convenient test for screening metallo-beta-lactamase-producing gram-negative bacteria by using thiol compounds. J Clin Microbiol, 2000, 38, 40-43.
168. Payne, D. J.; Hueso-Rodriguez, J. A.; Boyd, H.; Concha, N. O.; Janson, C. A.; Gilpin, M.; Bateson, J. H.; Cheever, C.; Niconovich, N. L.; Pearson, S.; Rittenhouse, S.; Tew, D.; Diez, E.; Perez, P.; De La Fuente, J.; Rees, M.; Rivera-Sagredo, A. Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-beta-lactamases. Antimicrob Agents Chemother, 2002, 46, 1880-1886.
169. Walter, M. W.; Felici, A.; Galleni, M.; Soto, R. P.; Adington, R. M.; Baldwin, J. E.; Frere, J. M.; Gololobov, M.; Schofield, C. J. Trifluoromethyl alcohol and ketone inhibitors of metallo-beta-lactamases. Bioorg Med Chem Lett, 1996, 6, 2455-2458.
170. Siemann, S.; Evanoff, D. P.; Marrone, L.; Clarke, A. J.; Viswanatha, T.; Dmitrienko, G. I. N-arylsulfonyl hydrazones as inhibitors of IMP-1 metallo-beta-lactamase. Antimicrob Agents Chemother, 2002, 46, 2450-2457.
171. Toney, J. H.; Hammond, G. G.; Fitzgerald, P. M.; Sharma, N.; Balkovec, J. M.; Rouen, G. P.; Olson, S. H.; Hammond, M. L.; Greenlee, M. L.; Gao, Y. D. Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-beta-lactamase. J Biol Chem, 2001, 276, 31913-31918.
172. Greenlee, M. L.; Laub, J. B.; Balkovec, J. M.; Hammond, M. L.; Hammond, G. G.; Pompliano, D. L.; Epstein-Toney, J. H. Synthesis and SAR of thioester and thiol inhibitors of IMP-1 metallo-beta-lactamase. Bioorg Med Chem Lett, 1999, 9, 2549-2554.
173. Nagano, R.; Adachi, Y.; Imamura, H.; Yamada, K.; Hashizume, T.; Morishima, H. Carbapenem derivatives as potential inhibitors of various beta-lactamases, including class B metallo-beta-lactamases. Antimicrob Agents Chemother, 1999, 43, 2497-2503.
174. Nagano, R.; Adachi, Y.; Hashizume, T.; Morishima, H. In vitro antibacterial activity and mechanism of action of J-111,225, a novel 1beta-methylcarbapenem, against transferable IMP-1 metallo-beta-lactamase producers. J Antimicrob Chemother, 2000, 45, 271-276.
175. Quiroga, M. I.; Franceschini, N.; Rossolini, G. M.; Gutkind, G.; Bonfiglio, G.; Franchino, L.; Amicosante, G. Interaction of cefotetan and the metallo-beta-lactamases produced in Aeromonas spp. and in vitro activity. Chemotherapy, 2000, 46, 177-183.
176. Tsang, W. Y.; Dhanda, A.; Schofield, C. J.; Frere, J. M.; Galleni, M.; Page, M. I. The inhibition of metallo-beta-lactamase by thioxo-cephalosporin derivatives. Bioorg Med Chem Lett, 2004, 14, 1737-1739.